Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2026—Sepsis is a major cause of pediatric morbidity and mortality worldwide. It is difficult to measure the number of pediatric sepsis cases since most estimates are based on administrative codes, and coding practices vary by institution. Medical record review offers greater accuracy in recording pediatric sepsis diagnoses, but it is labor intensive and subject to interrater variability.
July 2026—Hepatoid lung carcinomas, similar to hepatoid carcinomas of other sites, are defined as extrahepatic tumors exhibiting divergent hepatocellular differentiation. Uniquely, hepatoid carcinomas of the lung are reported to commonly express only HepPar1, which recognizes the mitochondrial enzyme carbamoyl-phosphate synthetase-1 (CPS1). HepPar1/CPS1 was recently found to accumulate in lung adenocarcinomas (LUAD) harboring STK11 mutations, presumably as a genotype-associated metabolic adaptation.
July 2026—Parkinson’s disease, which is characterized by loss of dopamine-producing neurons in the brain’s substantia nigra and the pathologic misfolding and accumulation of alpha-synuclein, can result in a range of motor and nonmotor symptoms that may vary by individual. The cardinal motor symptoms of Parkinson’s disease (PD) are bradykinesia (slowness of movement), resting tremor, rigidity, and postural instability. A prodromal phase of the disease can generate nonmotor symptoms, such as a reduced sense of smell years prior to the onset of cardinal motor symptoms.
July 2026—Apollo is a health care-scale multimodal foundation model designed to integrate longitudinal clinical data into unified virtual patient representations. It was developed by the authors using data from a major U.S. health care system and trained on approximately 25 billion clinical records from 7.2 million patients that spanned more than three decades. The data set incorporated 12 medical specialties and 28 clinical modalities, including pathology images, laboratory testing, clinical documentation, medications, and structured electronic health record data.
July 2026
Q. What is the recommended approach for determining the HIV status of patients who are taking HIV pre-exposure prophylaxis or have received oral PrEP within the past three months or intramuscular PrEP within the past 12 months? Read answer.
Q. Our providers pointed out that lipoprotein(a) results from different laboratories are discordant, so they asked us to bring the assay in-house. Is this a good idea? Read answer.
July 2026—Dedicated training in histology is increasingly getting short shrift as many academic medical institutions nationwide move to an organ system-based teaching structure. Recognizing this trend, a group of faculty and residents at the University of Wisconsin School of Medicine and Public Health are employing creativity, a simple software program, and a bit of teamwork to boost medical students’ exposure to the specialty.
July 2026—The volume of information pathology residents need to know by the end of residency to pass the board exams is extraordinarily large. Certain subspecialties within pathology such as hematopathology can be especially challenging because there are hundreds of CD markers, which can make memorizing them and their associated diseases difficult. Articles have been published on the overload and stress pathology trainees feel.
July 2026—The renewed restriction on remote participation in cytology workflows could have unintended consequences for access to and efficiency and continuity of care, write authors of a Correspondence published online in May in Nature Medicine.
